It was evidenced that LncRNA prostate cancer antigen 3 (PCA3) is overexpressed in 95% of prostate cancers and can be used as molecular markers [116] in prostate cancers, which was approved by the US food and drug administration in 2012 [117]. Here, PCA3 is linked to Familial prostate cancer.